Stereotaxis Inc (STXS)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • AMEX
Market Cap: $85.02M
Last updated: Nov 17, 2026 at 11:05 AM ET
Stereotaxis Inc (STXS) Earnings: Report Dates and Results
Stereotaxis (STXS) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Stereotaxis reported EPS of -$0.07, below the -$0.05 estimate. It beat the EPS estimate in 1 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
STXS has an expected report date of Mar 8, 2027.
STXS Earnings Call
The latest STXS earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 27 quarters below that had an estimate, STXS beat 5, missed 13 and matched 9. Revenue for the quarter ended Sep 30, 2026 was $8.93M, up 19.7% from $7.46M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.07 | -$0.05 | -$0.06 - -$0.05 | -40.00% | Miss | N/A | 2 | 0 up, 1 down | Nov 10, 2026 | $8.93M |
| Jun 30, 2026 | -$0.05 | -$0.03 | -$0.06 - -$0.03 | -66.67% | Miss | N/A | 3 | 1 up, 0 down | Aug 11, 2026 | $7.67M |
| Mar 31, 2026 | -$0.06 | -$0.06 | -$0.06 - -$0.04 | -10.05% | Miss | N/A | 3 | 1 up, 0 down | May 12, 2026 | $6.29M |
| Dec 31, 2025 | -$0.06 | -$0.06 | -$0.07 - -$0.06 | 0.00% | In line | N/A | 4 | N/A | Mar 9, 2026 | $8.64M |
| Sep 30, 2025 | -$0.07 | -$0.06 | -$0.07 - -$0.05 | -16.67% | Miss | N/A | 4 | 0 up, 0 down | Nov 11, 2025 | $7.46M |
| Jun 30, 2025 | -$0.05 | -$0.07 | -$0.08 - -$0.05 | +28.57% | Beat | N/A | 4 | 1 up, 0 down | Aug 7, 2025 | $8.80M |
| Mar 31, 2025 | -$0.07 | -$0.07 | -$0.09 - -$0.06 | 0.00% | In line | N/A | 4 | 0 up, 3 down | May 12, 2025 | $7.47M |
| Dec 31, 2024 | -$0.09 | -$0.07 | -$0.08 - -$0.04 | -38.46% | Miss | N/A | 4 | 0 up, 2 down | Mar 3, 2025 | $6.34M |
| Sep 30, 2024 | -$0.08 | -$0.05 | -$0.07 - -$0.03 | -60.00% | Miss | N/A | 4 | 0 up, 0 down | Nov 11, 2024 | $9.20M |
| Jun 30, 2024 | -$0.07 | -$0.05 | -$0.08 - -$0.04 | -40.00% | Miss | N/A | 4 | 0 up, 0 down | Aug 12, 2024 | $4.50M |
| Mar 31, 2024 | -$0.06 | -$0.06 | -$0.07 - -$0.06 | 0.00% | In line | N/A | 5 | 0 up, 0 down | May 13, 2024 | $6.88M |
| Dec 31, 2023 | -$0.07 | -$0.07 | -$0.07 - -$0.06 | 0.00% | In line | N/A | 5 | 0 up, 0 down | Mar 4, 2024 | $4.57M |
| Sep 30, 2023 | -$0.07 | -$0.06 | -$0.07 - -$0.05 | -16.67% | Miss | N/A | 5 | 0 up, 0 down | Nov 9, 2023 | $7.80M |
| Jun 30, 2023 | -$0.07 | -$0.07 | -$0.09 - -$0.05 | 0.00% | In line | N/A | 5 | 0 up, 0 down | Aug 10, 2023 | $7.86M |
| Mar 31, 2023 | -$0.07 | -$0.06 | -$0.07 - -$0.04 | -16.67% | Miss | N/A | 4 | 0 up, 0 down | May 9, 2023 | $6.55M |
| Dec 31, 2022 | -$0.06 | -$0.07 | -$0.08 - -$0.04 | +14.29% | Beat | N/A | 6 | 0 up, 0 down | Mar 3, 2023 | $7.30M |
| Sep 30, 2022 | -$0.07 | -$0.06 | -$0.07 - -$0.05 | -16.67% | Miss | N/A | 8 | 0 up, 0 down | Nov 10, 2022 | $7.66M |
| Jun 30, 2022 | -$0.07 | -$0.06 | N/A | -16.67% | Miss | N/A | N/A | 0 up, 0 down | Aug 9, 2022 | $6.15M |
| Mar 31, 2022 | -$0.06 | -$0.06 | -$0.08 - -$0.04 | 0.00% | In line | N/A | 6 | 0 up, 0 down | May 10, 2022 | $7.04M |
| Dec 31, 2021 | -$0.05 | -$0.05 | -$0.07 - -$0.03 | 0.00% | In line | N/A | 6 | N/A | Mar 3, 2022 | $8.24M |
| Sep 30, 2021 | -$0.07 | -$0.04 | -$0.07 - -$0.02 | -75.00% | Miss | N/A | 3 | 1 up, 0 down | Nov 11, 2021 | $9.11M |
| Jun 30, 2021 | -$0.05 | -$0.03 | -$0.04 - -$0.02 | -66.67% | Miss | N/A | 4 | N/A | Aug 10, 2021 | $9.05M |
| Mar 31, 2021 | -$0.02 | -$0.03 | -$0.03 - -$0.02 | +33.33% | Beat | N/A | 3 | N/A | May 10, 2021 | $8.62M |
| Dec 31, 2020 | -$0.02 | -$0.03 | -$0.04 - -$0.02 | +33.33% | Beat | N/A | 3 | N/A | Feb 25, 2021 | N/A |
| Sep 30, 2020 | -$0.03 | -$0.03 | -$0.05 - -$0.02 | 0.00% | In line | N/A | 3 | N/A | Nov 9, 2020 | $17.41M |
| Jun 30, 2020 | -$0.03 | -$0.05 | -$0.05 - -$0.05 | +40.00% | Beat | N/A | 2 | N/A | Aug 6, 2020 | $5.35M |
| Mar 31, 2020 | -$0.03 | -$0.03 | -$0.03 - -$0.03 | 0.00% | In line | N/A | 2 | N/A | May 5, 2020 | $5.76M |
| Dec 31, 2019 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 10, 2020 | N/A |
| Sep 30, 2019 | $0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2019 | $8.20M |
| Jun 30, 2019 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 8, 2019 | $13.35M |
| Mar 31, 2019 | -$0.04 | N/A | N/A | N/A | N/A | -500.0% | N/A | N/A | May 9, 2019 | $7.00M |
| Dec 31, 2018 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 12, 2019 | $7.27M |
| Sep 30, 2018 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 12, 2018 | $7.56M |
| Jun 30, 2018 | -$0.02 | N/A | N/A | N/A | N/A | -300.0% | N/A | N/A | Aug 7, 2018 | $7.55M |
| Mar 31, 2018 | $0.01 | N/A | N/A | N/A | N/A | 0.0% | N/A | N/A | May 14, 2018 | $6.97M |
| Dec 31, 2017 | -$0.13 | N/A | N/A | N/A | N/A | -155.6% | N/A | N/A | Mar 6, 2018 | $7.56M |
| Sep 30, 2017 | -$0.21 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 9, 2017 | $8.14M |
| Jun 30, 2017 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 10, 2017 | $8.47M |
| Mar 31, 2017 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 8, 2017 | $6.98M |
| Dec 31, 2016 | $0.23 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 16, 2017 | $7.31M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.25, after -$0.30 the year before. It was -$0.54 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.25 | N/A |
| Dec 31, 2024 | -$0.30 | N/A |
| Dec 31, 2023 | -$0.28 | N/A |
| Dec 31, 2022 | -$0.26 | N/A |
| Dec 31, 2021 | -$0.19 | N/A |
| Dec 31, 2020 | -$0.11 | N/A |
| Dec 31, 2019 | -$0.09 | N/A |
| Dec 31, 2018 | -$0.04 | N/A |
| Dec 31, 2017 | -$0.32 | N/A |
| Dec 31, 2016 | -$0.54 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 4,800 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 4,756 | 6 | |
| 2025Q4 | Dec 31, 2025 | 6,383 | 8 | |
| 2025Q3 | Sep 30, 2025 | 3,884 | 7 | |
| 2025Q2 | Jun 30, 2025 | 3,230 | 5 | |
| 2025Q1 | Mar 31, 2025 | 6,199 | 7 | |
| 2024Q4 | Dec 31, 2024 | 6,197 | 6 | |
| 2024Q3 | Sep 30, 2024 | 5,500 | 7 | |
| 2024Q2 | Jun 30, 2024 | 7,081 | 6 |
2026Q1 Earnings Call
Opening remarks
David Leo Fischel Chairman and CEO It is now my pleasure to turn the floor over to your host, David Leo Fischel, chairman and CEO of Stereotaxis. Thank you, operator, and good afternoon, everyone. Stereotaxis has had an amazing start to this year. While our reported quarterly numbers do not yet reflect it, we are going through one of the most exciting periods in Stereotaxis' history, given the amount of progress, the initial commercial green shoots of success, and the clarity on the opportunity ahead of us. These give us confidence in our overall vision reaching a new level of maturity in our near-term and long-term growth. In my prepared remarks, I will touch upon the key areas of progress, the commercial green shoots, and the opportunities ahead of us. Kimberly will then review our first-quarter results, and we will open the line to questions. The most notable achievement of the past year has been a string of regulatory approvals in the U.S. and Europe for an entirely new foundational ecosystem of products. While Stereotaxis has a long history, our clinical and commercial experience is nearly all with first-generation technology from twenty years ago. After spending the past eight years and over $75 million rebuilding an R&D pipeline, we brought to market an entirely new foundation of products. In just the past few months, we received four U.S. FDA regulatory approvals: for a complex surgical robot, robotically steered therapeutic and diagnostic catheters, and a digital surgery cockpit. Outside of the U.S., we received multiple approvals in Europe and China. These product approvals are not just incremental innovations, but rather they structurally change our opportunity. We essentially developed a fresh new start-up company on the shoulders of our legacy technology and funded by our legacy business. The streak of regulatory success that began last year continued in the first part of this year, with two essential FDA approvals. First, in January, we received PMA approval for the MAGIC cardiac ablation catheter. Then just last month, we received FDA clearance for Synchrony, our digital surgery cockpit that introduces connectivity and intelligence to the operating room. MAGIC is Stereotaxis' first proprietary therapeutic catheter and is the first ablation catheter ever to be approved by the FDA specifically for arrhythmia patients with complex congenital heart disease. The catheter strategically allows us to overcome our historical dependency on Johnson & Johnson, and to participate robustly in the recurring revenue of each procedure. Following regulatory approval, we recently announced that we began first MAGIC procedures at multiple U.S. hospitals. Those procedures have gone well.
Frequently Asked Questions About STXS
When is Stereotaxis's next earnings date?
Stereotaxis's next earnings report is expected for Mar 8, 2027.
Did STXS beat earnings estimates last quarter?
No. Stereotaxis reported EPS of -$0.07 for the quarter ended Sep 30, 2026, below the -$0.05 estimate by 40.00%.
What EPS do analysts expect from STXS next quarter?
The consensus EPS estimate for Stereotaxis for the quarter ending Dec 31, 2026 is -$0.05 from 5 analysts, with estimates from -$0.05 to -$0.04.
How often does STXS beat earnings estimates?
Stereotaxis beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -17.91%.
STXS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors